Conditions: Gastroesophageal Reflux Disease
Keywords: Drug Therapy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 104
Healthy volunteers: no

Brief summary:
The purpose of this study was to assess the safety and effectiveness of once daily oral administration of dexlansoprazole delayed-release capsules in adolescent participants with symptomatic non-erosive gastroesophageal reflux disease (GERD).

Detailed description:

Arms:
arm 1: Dexlansoprazole 30 mg delayed-release capsules orally once daily for up to 4 weeks.

Interventions: intervention 1: Dexlansoprazole
Intervention descriptions: intervention 1: Dexlansoprazole delayed-release capsules.

Protocol document: